Use AirSupra for Asthma Exacerbations
For adults with asthma experiencing exacerbations or worsening symptoms, use AirSupra (albuterol/budesonide) as your rescue inhaler rather than albuterol alone. Breztri (budesonide/formoterol/glycopyrrolate) is not indicated for acute exacerbations—it's a maintenance therapy for COPD and uncontrolled asthma, not a rescue medication.
Why AirSupra is the Clear Choice
AirSupra is FDA-approved specifically for as-needed treatment or prevention of bronchoconstriction AND to reduce the risk of exacerbations in adults ≥18 years with asthma 1. This dual indication directly addresses your clinical scenario.
The MANDALA trial demonstrated that AirSupra (albuterol 180 mcg/budesonide 160 mcg) reduced severe asthma exacerbation risk by 28% compared to albuterol alone (HR 0.72; 95% CI: 0.60-0.86; p<0.001) 1, 2. The annualized exacerbation rate dropped from 0.60 to 0.46 events per patient-year—a 24% reduction 1. Critically, patients also required 40 mg less systemic corticosteroids annually (87 mg vs 127 mg) 1.
The Physiological Rationale
When asthma symptoms worsen, patients face both acute bronchoconstriction AND escalating airway inflammation. Traditional SABA-only rescue therapy addresses bronchospasm but ignores the inflammatory component, leaving patients vulnerable to progression toward severe exacerbations 3.
AirSupra intervenes during this "window of opportunity" by delivering both rapid bronchodilation (albuterol) and anti-inflammatory action (budesonide) with each rescue dose 3. The budesonide component exerts both genomic and non-genomic anti-inflammatory effects that suppress the inflammatory cascade driving exacerbation risk 3.
Clinical Application Algorithm
For Moderate-to-Severe Asthma (on maintenance ICS or ICS-LABA):
- Prescribe AirSupra as rescue therapy in addition to their existing maintenance regimen
- Patients use 2 inhalations as needed for symptoms
- This approach was validated in MANDALA where all patients continued their maintenance therapy 1
- Benefits were consistent regardless of baseline exacerbation history, lung function, or maintenance therapy intensity 1
For Mild Asthma:
- AirSupra can be used as the sole therapy (no separate maintenance inhaler needed)
- This represents a paradigm shift from traditional SABA-only approaches 3
Why Not Breztri?
Breztri contains budesonide/glycopyrrolate/formoterol and is designed for twice-daily maintenance therapy in uncontrolled asthma or COPD 4. The KALOS/LOGOS trials evaluated Breztri for chronic disease control, not acute symptom relief 4. Key distinctions:
- No rapid-acting bronchodilator: Formoterol has 12-hour duration but slower onset than albuterol
- Contains LAMA (glycopyrrolate): Adds anticholinergic component unnecessary for acute rescue
- Dosing schedule: Designed for scheduled twice-daily use, not as-needed rescue
- Study population: Evaluated in patients already on medium-to-high dose ICS-LABA requiring escalation 4
Important Caveats
AirSupra is NOT approved for maintenance therapy or single maintenance and reliever therapy (SMART) 1. If patients need daily controller therapy, they require a separate maintenance inhaler.
The older NAEPP EPR-3 guidelines (2007) recommend SABA plus systemic corticosteroids for moderate-to-severe exacerbations 5, 6, but these predate AirSupra's development. The 2020 NAEPP updates conditionally recommend as-needed ICS-SABA used concomitantly for mild persistent asthma 7, supporting the AirSupra approach.
Common pitfall: Don't confuse AirSupra with budesonide-formoterol combinations used in SMART regimens 8, 9, 10. While both involve ICS-bronchodilator combinations, formoterol-based products can serve dual maintenance/rescue roles, whereas AirSupra with albuterol is rescue-only 11.
Bottom Line
Prescribe AirSupra as rescue therapy for any adult with asthma experiencing exacerbations. The combination addresses both bronchoconstriction and inflammation simultaneously, reducing exacerbation risk by nearly 30% compared to SABA alone while decreasing systemic corticosteroid burden 1, 2. Breztri has no role in acute exacerbation management—reserve it for patients requiring maintenance triple therapy escalation.